CURE250516P190000
- 0.00
- 0.000.00%
Direxion Daily Healthcare Bull 3X Shares Newsroom
Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
WeightWatchers Rises on Partnership With Eli Lilly to Enhance Zepbound Access
UnitedHealth Group Analyst Ratings
Abbvie: FDA Approves RINVOQ, 15 Mg, Once Daily, For Treatment Of Adults With Giant Cell Arteritis
Merck to Build $1B Delaware Plant to Ensure Domestic Supply of Keytruda - Report
Warren Buffett's 60-Year Legacy: What to Watch for at Berkshire Hathaway Shareholders Meeting?
Nvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report
Goldman Sachs: Oral weight loss drugs will be one of the most promising new medications in recent years!
Goldman Sachs predicts that by 2030, oral weight loss drugs will account for 24% of the total weight loss drug market, and Eli Lilly and Co will lead this segment with its orforglipron. Next, pay close attention to the third-quarter results of the ATTAIN-1 trial announced by Eli Lilly, which will be the first reading of orforglipron in the field of obesity and the most important next catalyst for the oral obesity drug market.
Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
AbbVie's Options Frenzy: What You Need to Know
Is Thermo Fisher Scientific Gaining or Losing Market Support?
Tariffs Bite Dan Loeb's Portfolio: Thermo Fisher Hit Hard, Discover Shines
A Look Into Abbott Laboratories Inc's Price Over Earnings
9 Health Care Stocks Whale Activity In Today's Session
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $205
Scribe Therapeutics And Prevail To Present New Preclinical Data On SiXAAV Technology From Collaboration At ASGCT Annual Meeting